Related Experiment Video
Updated: Apr 18, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Emerging therapy for adrenocortical carcinoma
Rachel D Aufforth1, Naris Nilubol1
1Endocrine Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Abstract:
Adrenocortical carcinoma (ACC) is a very rare and aggressive tumor with dismal outcomes. Best current treatments include complete surgical resection for localized resectable disease and systemic therapy with mitotane alone or in combination for advanced ACC. Advances in molecular genetic profiling of ACC have created multiple new targets for potential treatment options in ACC. This article reviews the current treatment options available for ACC and discusses the potential new targets identified through molecular profiling.
Insights
Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. Current treatments involve surgery or mitotane, but new molecular targets offer future treatment possibilities.
Area of Science:
- Oncology
- Endocrinology
- Cancer Genetics
Background:
- Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumor.
- Current treatments include surgical resection and systemic therapy with mitotane.
- Outcomes for advanced ACC remain poor.
Purpose of the Study:
- To review current treatment options for adrenocortical carcinoma.
- To discuss emerging molecular targets for ACC treatment.
Main Methods:
- Literature review of current ACC treatments.
- Analysis of recent molecular profiling studies in ACC.
Main Results:
- Complete surgical resection is standard for localized disease.
- Mitotane is the primary systemic therapy for advanced ACC.
- Molecular profiling has identified several new potential therapeutic targets.
Conclusions:
- Despite advances, ACC remains challenging to treat.
- Targeted therapies based on molecular profiling hold promise for future ACC treatment strategies.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Treatment Resistent Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...